---
author: []
related: []
publisher:
  url: 'http://www.investorideas.com'
  name: Investorideas
  favicon: 'http://www.investorideas.com/favicon.ico'
  domain: www.investorideas.com
keywords:
  - itp
  - rigel
  - fostamatinib
  - platelet
  - patients
  - phase
  - forward-looking
  - clinical
  - study
  - investorideas
description: >-
  Pharma News: #Rigel's (NASDAQ: $RIGL) #Fostamatinib Meets Primary Endpoint in
  Phase 3 Study in Chronic ITP
inLanguage: en
app_links: []
isBasedOnUrl: 'http://www.investorideas.com/news/2016/biotech/08301RIGL.asp'
title: >-
  Investorideas.com - #Pharma News: #Rigel's (NASDAQ: $RIGL) #Fostamatinib Meets
  Primary Endpoint in Phase 3 Study in Chronic ITP
datePublished: '2016-08-30T17:24:21.515Z'
dateModified: '2016-08-30T17:24:15.281Z'
via: {}
starred: false
sourcePath: _posts/2016-08-30-investorideascom-pharma-news-rigels-nasdaq-dollarrigl.md
inFeed: true
hasPage: false
inNav: false
_context: 'http://schema.org'
_type: MediaObject

---
<article style=""><h1>Investorideas.com - #Pharma News: #Rigel's (NASDAQ: $RIGL) #Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP</h1><p>Pharma News: #Rigel's (NASDAQ: $RIGL) #Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP</p><img src="http://www.investorideas.com/news/2016/biotech/images/083016-1.jpg" /></article>